Clinical Trial Update: Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated bromfenac to reduce inflammation after cataract surgery in patients with pseudoexfoliation syndrome. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Pseudoexfoliation Syndrome

Drugs mentioned

• BROMFENAC (Bromfenac)

Snippet

Sponsor: Azienda USL Reggio Emilia - IRCCS | Conditions: Cataract, Pseudoexfoliation Syndrome | Phase 4 | Status: COMPLETED